TL:DR Mounjaro, Zepbound, Wegovy and Ozempic linked to reduced chance of getting MS!

From the Article:

The use of obesity medications — approved drugs for treating diabetes and promoting weight loss — is associated with a reduced chance of developing multiple sclerosis (MS), according to real-world data from the U.S. Food and Drug Administration (FDA), a study found.

In particular, medicines that activate a receptor called GLP-1, which lowers blood glucose or blood sugar levels, all showed potential protective effects against MS.

“These findings suggest a potential for repurposing these medications for MS,” the researchers wrote.

Their study, “Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database,” was published in the journal Therapeutic Advances in Neurological Disorders.

Obesity is a well-known driver of chronic inflammation in the body, which can help set the stage for the development of MS, an inflammatory disorder affecting the brain and spinal cord.

Research has shown that obesity in early childhood or adolescence increases the risk of MS. It also worsens outcomes for newly diagnosed patients, and is linked to less favorable responses to disease-modifying therapies.